Sequential treatment with afatinib and osimertinib in patients with
            <i>EGFR</i>
            mutation-positive non-small-cell lung cancer: an observational study

DOI Web Site 6 Citations

Maximilian J Hochmair

Department of Respiratory & Critical Care Medicine, Ludwig Boltzmann Institute of COPD & Respiratory Epidemiology, Otto Wagner Hospital, Sanatoriumstrasse 2, 1140Vienna, Austria
Alessandro Morabito

Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G.Pascale’-IRCCS, 80131Napoli, Italy
Desiree Hao

Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada
Cheng-Ta Yang

Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Ross A Soo

Department of Haematology-Oncology, National University Hospital Singapore
James C-H Yang

Department of Oncology, National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei, Taiwan
Rasim Gucalp

Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
Balazs Halmos

Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
Lara Wang

Clinical Trials, Boehringer Ingelheim Taiwan Limited Taiwan
Amanda Golembesky

Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
Angela Märten

Medical Affairs Oncology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
Tanja Cufer

Medical Faculty, University Clinic Golnik, University of Ljubljana, Ljubliana, Slovenia

Journal

Future Oncology

Future Oncology 14 (27), 2861-2874, 2018-10-19

Informa UK Limited

Back to top